Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 25 to 36 of 48 entries
Sorted by: Best Match Show Resources per page
STOP 301: A Phase 3, open-label study of safety, tolerability, and exploratory efficacy of INP104, Precision Olfactory Delivery (POD.

Headache

Smith TR, Winner P, Aurora SK, Jeleva M, Hocevar-Trnka J, Shrewsbury SB.
PMID: 34363701
Headache. 2021 Sep;61(8):1214-1226. doi: 10.1111/head.14184. Epub 2021 Aug 07.

OBJECTIVE: To report the safety, tolerability, exploratory efficacy, and patient acceptability of INP104 for the acute treatment of migraine from the Phase 3 STOP 301 trial.BACKGROUND: Dihydroergotamine (DHE) has long been used to treat migraine, but intravenous administration is...

Cite
Smith TR, Winner P, Aurora SK, et al. STOP 301: A Phase 3, open-label study of safety, tolerability, and exploratory efficacy of INP104, Precision Olfactory Delivery (POD. Headache. 2021;61(8):1214-1226doi: 10.1111/head.14184.
Smith, T. R., Winner, P., Aurora, S. K., Jeleva, M., Hocevar-Trnka, J., & Shrewsbury, S. B. (2021). STOP 301: A Phase 3, open-label study of safety, tolerability, and exploratory efficacy of INP104, Precision Olfactory Delivery (POD. Headache, 61(8), 1214-1226. https://doi.org/10.1111/head.14184
Smith, Timothy R, et al. "STOP 301: A Phase 3, open-label study of safety, tolerability, and exploratory efficacy of INP104, Precision Olfactory Delivery (POD." Headache vol. 61,8 (2021): 1214-1226. doi: https://doi.org/10.1111/head.14184
Smith TR, Winner P, Aurora SK, Jeleva M, Hocevar-Trnka J, Shrewsbury SB. STOP 301: A Phase 3, open-label study of safety, tolerability, and exploratory efficacy of INP104, Precision Olfactory Delivery (POD. Headache. 2021 Sep;61(8):1214-1226. doi: 10.1111/head.14184. Epub 2021 Aug 07. PMID: 34363701.
Copy Download .nbib Format: NLM
Development and Evaluation of an Integrated Outpatient Infusion Care Model for the Treatment of Pediatric Headache.

Pediatric neurology

Shapiro HFJ, Sant J, Minster A, Antonelli RC.
PMID: 34959159
Pediatr Neurol. 2021 Dec 02;127:41-47. doi: 10.1016/j.pediatrneurol.2021.11.012. Epub 2021 Dec 02.

BACKGROUND: Care for pediatric patients with headache often occurs in high-cost settings such as emergency departments (EDs) and inpatient settings. Outpatient infusion centers have the potential to reduce care costs for pediatric headache management.METHODS: In this quality improvement study,...

Cite
Shapiro HFJ, Sant J, Minster A, et al. Development and Evaluation of an Integrated Outpatient Infusion Care Model for the Treatment of Pediatric Headache. Pediatr Neurol. 2021;127:41-47doi: 10.1016/j.pediatrneurol.2021.11.012.
Shapiro, H. F. J., Sant, J., Minster, A., & Antonelli, R. C. (2021). Development and Evaluation of an Integrated Outpatient Infusion Care Model for the Treatment of Pediatric Headache. Pediatric neurology, 12741-47. https://doi.org/10.1016/j.pediatrneurol.2021.11.012
Shapiro, Hannah F J, et al. "Development and Evaluation of an Integrated Outpatient Infusion Care Model for the Treatment of Pediatric Headache." Pediatric neurology vol. 127 (2021): 41-47. doi: https://doi.org/10.1016/j.pediatrneurol.2021.11.012
Shapiro HFJ, Sant J, Minster A, Antonelli RC. Development and Evaluation of an Integrated Outpatient Infusion Care Model for the Treatment of Pediatric Headache. Pediatr Neurol. 2021 Dec 02;127:41-47. doi: 10.1016/j.pediatrneurol.2021.11.012. Epub 2021 Dec 02. PMID: 34959159.
Copy Download .nbib Format: NLM
Second-line interventions for migraine in the emergency department: A narrative review.

Headache

Kazi F, Manyapu M, Fakherddine M, Mekuria K, Friedman BW.
PMID: 34806767
Headache. 2021 Nov;61(10):1467-1474. doi: 10.1111/head.14239. Epub 2021 Nov 22.

OBJECTIVE: Millions of patients present to US emergency departments (ED) annually for the treatment of migraine. First-line treatments, including metoclopramide, prochlorperazine, and sumatriptan, fail to provide sufficient relief in up to one-third of treated patients. In this narrative review,...

Cite
Kazi F, Manyapu M, Fakherddine M, et al. Second-line interventions for migraine in the emergency department: A narrative review. Headache. 2021;61(10):1467-1474doi: 10.1111/head.14239.
Kazi, F., Manyapu, M., Fakherddine, M., Mekuria, K., & Friedman, B. W. (2021). Second-line interventions for migraine in the emergency department: A narrative review. Headache, 61(10), 1467-1474. https://doi.org/10.1111/head.14239
Kazi, Farnam, et al. "Second-line interventions for migraine in the emergency department: A narrative review." Headache vol. 61,10 (2021): 1467-1474. doi: https://doi.org/10.1111/head.14239
Kazi F, Manyapu M, Fakherddine M, Mekuria K, Friedman BW. Second-line interventions for migraine in the emergency department: A narrative review. Headache. 2021 Nov;61(10):1467-1474. doi: 10.1111/head.14239. Epub 2021 Nov 22. PMID: 34806767.
Copy Download .nbib Format: NLM
Symptomatic treatment of migraine: when to use NSAIDs, triptans, or opiates.

Current treatment options in neurology

Taylor FR, Kaniecki RG.
PMID: 21125432
Curr Treat Options Neurol. 2011 Feb;13(1):15-27. doi: 10.1007/s11940-010-0107-4.

OPINION STATEMENT: Migraine is a biologic disorder of the brain characterized by a heterogeneous array of symptoms and episodes of disabling headache. By definition, such attacks last between 4 and 72 h without treatment, with the disability arising from...

Cite
Taylor FR, Kaniecki RG. Symptomatic treatment of migraine: when to use NSAIDs, triptans, or opiates. Curr Treat Options Neurol. 2011;13(1):15-27doi: 10.1007/s11940-010-0107-4.
Taylor, F. R., & Kaniecki, R. G. (2011). Symptomatic treatment of migraine: when to use NSAIDs, triptans, or opiates. Current treatment options in neurology, 13(1), 15-27. https://doi.org/10.1007/s11940-010-0107-4
Taylor, Frederick R, and Kaniecki, Robert G. "Symptomatic treatment of migraine: when to use NSAIDs, triptans, or opiates." Current treatment options in neurology vol. 13,1 (2011): 15-27. doi: https://doi.org/10.1007/s11940-010-0107-4
Taylor FR, Kaniecki RG. Symptomatic treatment of migraine: when to use NSAIDs, triptans, or opiates. Curr Treat Options Neurol. 2011 Feb;13(1):15-27. doi: 10.1007/s11940-010-0107-4. PMID: 21125432.
Copy Download .nbib Format: NLM
[Headache in children.].

Schmerz (Berlin, Germany)

Pothmann R.
PMID: 18415208
Schmerz. 1990 Mar;4(1):7-13. doi: 10.1007/BF02527824.

Idiopathic headaches are probably the most common problem in schoolchildren. The prevalence increases up to 70% in 14-year-old adolescents, with migraines ranging from 10% to 20%. Tension headaches are often understandable on a psychosocial and behavioral basis; in migraine,...

Cite
Pothmann R. Kopfschmerzen bei Kindern. [Headache in children.]. Schmerz. 1990;4(1):7-13doi: 10.1007/BF02527824.
Pothmann, R. (1990). Kopfschmerzen bei Kindern. [Headache in children.]. Schmerz (Berlin, Germany), 4(1), 7-13. https://doi.org/10.1007/BF02527824
Pothmann, R. "Kopfschmerzen bei Kindern." [Headache in children.]. Schmerz (Berlin, Germany) vol. 4,1 (1990): 7-13. doi: https://doi.org/10.1007/BF02527824
Pothmann R. Kopfschmerzen bei Kindern. [Headache in children.]. Schmerz. 1990 Mar;4(1):7-13. doi: 10.1007/BF02527824. German. PMID: 18415208.
Copy Download .nbib Format: NLM
Treatment of headache following triptan failure after successful triptan therapy.

Current treatment options in neurology

Lenaerts ME, Couch JR.
PMID: 25962622
Curr Treat Options Neurol. 2015 Jun;17(6):353. doi: 10.1007/s11940-015-0353-6.

OPINION STATEMENT: Triptans should remain the first choice in migraine abortive treatment. They are not always effective or adequate for specific patients. Before declaring a triptan in appropriate for a given patient, the provider ought to be analytical about...

Cite
Lenaerts ME, Couch JR. Treatment of headache following triptan failure after successful triptan therapy. Curr Treat Options Neurol. 2015;17(6):353doi: 10.1007/s11940-015-0353-6.
Lenaerts, M. E., & Couch, J. R. (2015). Treatment of headache following triptan failure after successful triptan therapy. Current treatment options in neurology, 17(6), 353. https://doi.org/10.1007/s11940-015-0353-6
Lenaerts, Marc E P, and Couch, James R. "Treatment of headache following triptan failure after successful triptan therapy." Current treatment options in neurology vol. 17,6 (2015): 353. doi: https://doi.org/10.1007/s11940-015-0353-6
Lenaerts ME, Couch JR. Treatment of headache following triptan failure after successful triptan therapy. Curr Treat Options Neurol. 2015 Jun;17(6):353. doi: 10.1007/s11940-015-0353-6. PMID: 25962622.
Copy Download .nbib Format: NLM
Treatment of pediatric migraine.

Current treatment options in neurology

O'Brien HL, Kabbouche MA, Kacperski J, Hershey AD.
PMID: 25617222
Curr Treat Options Neurol. 2015 Jan;17(1):326. doi: 10.1007/s11940-014-0326-1.

OPINION STATEMENT: The diagnosis of migraine in the pediatric population is increasing as providers are becoming more familiar with recognizing the condition. Over-the-counter and migraine-specific treatment, once considered off-label, have proven to be effective, especially if given at the...

Cite
O'Brien HL, Kabbouche MA, Kacperski J, et al. Treatment of pediatric migraine. Curr Treat Options Neurol. 2015;17(1):326doi: 10.1007/s11940-014-0326-1.
O'Brien, H. L., Kabbouche, M. A., Kacperski, J., & Hershey, A. D. (2015). Treatment of pediatric migraine. Current treatment options in neurology, 17(1), 326. https://doi.org/10.1007/s11940-014-0326-1
O'Brien, Hope L, et al. "Treatment of pediatric migraine." Current treatment options in neurology vol. 17,1 (2015): 326. doi: https://doi.org/10.1007/s11940-014-0326-1
O'Brien HL, Kabbouche MA, Kacperski J, Hershey AD. Treatment of pediatric migraine. Curr Treat Options Neurol. 2015 Jan;17(1):326. doi: 10.1007/s11940-014-0326-1. PMID: 25617222.
Copy Download .nbib Format: NLM
Molecular modelling studies unveil potential binding sites on human serum albumin for selected experimental and .

Saudi journal of biological sciences

Bahadur Gurung A, Ajmal Ali M, Lee J, Abul Farah M, Mashay Al-Anazi K, Sami H.
PMID: 34548836
Saudi J Biol Sci. 2021 Sep 17; doi: 10.1016/j.sjbs.2021.09.042. Epub 2021 Sep 17.

Human serum albumin (HSA) is the most prevalent protein in the blood plasma which binds an array of exogenous compounds. Drug binding to HSA is an important consideration when developing new therapeutic molecules, and it also aids in understanding...

Cite
Bahadur Gurung A, Ajmal Ali M, Lee J, et al. Molecular modelling studies unveil potential binding sites on human serum albumin for selected experimental and . Saudi J Biol Sci. 2021;doi: 10.1016/j.sjbs.2021.09.042.
Bahadur Gurung, A., Ajmal Ali, M., Lee, J., Abul Farah, M., Mashay Al-Anazi, K., & Sami, H. (2021). Molecular modelling studies unveil potential binding sites on human serum albumin for selected experimental and . Saudi journal of biological sciences, . https://doi.org/10.1016/j.sjbs.2021.09.042
Bahadur Gurung, Arun, et al. "Molecular modelling studies unveil potential binding sites on human serum albumin for selected experimental and ." Saudi journal of biological sciences vol. (2021). doi: https://doi.org/10.1016/j.sjbs.2021.09.042
Bahadur Gurung A, Ajmal Ali M, Lee J, Abul Farah M, Mashay Al-Anazi K, Sami H. Molecular modelling studies unveil potential binding sites on human serum albumin for selected experimental and . Saudi J Biol Sci. 2021 Sep 17; doi: 10.1016/j.sjbs.2021.09.042. Epub 2021 Sep 17. PMID: 34548836; PMCID: PMC8447726.
Copy Download .nbib Format: NLM
Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology

Bayés M, Rabasseda X, Prous JR.
PMID: 12224444
Methods Find Exp Clin Pharmacol. 2002 Jul-Aug;24(6):371-91.

Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the following tables has been retrieved from the Clinical Studies knowledge area of Prous Science Integrity, the drug...

Cite
Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2002;24(6):371-91
Bayés, M., Rabasseda, X., & Prous, J. R. (2002). Gateways to clinical trials. Methods and findings in experimental and clinical pharmacology, 24(6), 371-91.
Bayés, M, et al. "Gateways to clinical trials." Methods and findings in experimental and clinical pharmacology vol. 24,6 (2002): 371-91.
Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2002 Jul-Aug;24(6):371-91. PMID: 12224444.
Copy Download .nbib Format: NLM
Effects of clonidine and alpha-adrenoceptor antagonists on motor activity in DSP4-treated mice I: dose-, time- and parameter-dependency.

Neurotoxicity research

Archer T, Fredriksson A.
PMID: 12835092
Neurotox Res. 2000 Apr;1(4):235-47. doi: 10.1007/BF03033254.

In three experiments the acute effects of clonidine administration upon locomotor and rearing behaviour of mice pretreated with the selective noradrenaline (NA) neurotoxin, DSP4 (1 x 75 mg/kg, i.p.) 10-12 days previously, were studied. Clonidine (0.01, 0.05, 0.25, 1.25...

Cite
Archer T, Fredriksson A. Effects of clonidine and alpha-adrenoceptor antagonists on motor activity in DSP4-treated mice I: dose-, time- and parameter-dependency. Neurotox Res. 2000;1(4):235-47doi: 10.1007/BF03033254.
Archer, T., & Fredriksson, A. (2000). Effects of clonidine and alpha-adrenoceptor antagonists on motor activity in DSP4-treated mice I: dose-, time- and parameter-dependency. Neurotoxicity research, 1(4), 235-47. https://doi.org/10.1007/BF03033254
Archer, T, and Fredriksson, A. "Effects of clonidine and alpha-adrenoceptor antagonists on motor activity in DSP4-treated mice I: dose-, time- and parameter-dependency." Neurotoxicity research vol. 1,4 (2000): 235-47. doi: https://doi.org/10.1007/BF03033254
Archer T, Fredriksson A. Effects of clonidine and alpha-adrenoceptor antagonists on motor activity in DSP4-treated mice I: dose-, time- and parameter-dependency. Neurotox Res. 2000 Apr;1(4):235-47. doi: 10.1007/BF03033254. PMID: 12835092.
Copy Download .nbib Format: NLM
[Drug treatment as migraine prophylaxis.].

Schmerz (Berlin, Germany)

Diener HC, Ziegler A.
PMID: 18415382
Schmerz. 1989 Dec;3(4):227-32. doi: 10.1007/BF02527386.

If migraine attacks occur more frequently than 2 times a month, treatment of the acute attack with analgesics and ergotamine becomes problematic. An acute relief of migraine symptoms will be achieved only at the risk of developing a drug-induced...

Cite
Diener HC, Ziegler A. Medikamentöse Migräneprophylaxe. [Drug treatment as migraine prophylaxis.]. Schmerz. 1989;3(4):227-32doi: 10.1007/BF02527386.
Diener, H. C., & Ziegler, A. (1989). Medikamentöse Migräneprophylaxe. [Drug treatment as migraine prophylaxis.]. Schmerz (Berlin, Germany), 3(4), 227-32. https://doi.org/10.1007/BF02527386
Diener, H C, and Ziegler, A. "Medikamentöse Migräneprophylaxe." [Drug treatment as migraine prophylaxis.]. Schmerz (Berlin, Germany) vol. 3,4 (1989): 227-32. doi: https://doi.org/10.1007/BF02527386
Diener HC, Ziegler A. Medikamentöse Migräneprophylaxe. [Drug treatment as migraine prophylaxis.]. Schmerz. 1989 Dec;3(4):227-32. doi: 10.1007/BF02527386. German. PMID: 18415382.
Copy Download .nbib Format: NLM
TREATMENT OF MIGRAINE-Results with Dihydroergocornine Methanesulfonate (DHO-180) and Other Ergot Derivatives.

California medicine

Bercel NA.
PMID: 18731688
Calif Med. 1950 Apr;72(4):234-8.

A comparison of nicotinic acid, a non-narcotic analgesic and a series of injectable and oral ergot preparations tested by various methods in treating 40 patients with typical migraine indicate that ergot alkaloids are far superior in producing symptomatic relief.A...

Cite
Bercel NA. TREATMENT OF MIGRAINE-Results with Dihydroergocornine Methanesulfonate (DHO-180) and Other Ergot Derivatives. Calif Med. 1950;72(4):234-8
Bercel, N. A. (1950). TREATMENT OF MIGRAINE-Results with Dihydroergocornine Methanesulfonate (DHO-180) and Other Ergot Derivatives. California medicine, 72(4), 234-8.
Bercel, N A. "TREATMENT OF MIGRAINE-Results with Dihydroergocornine Methanesulfonate (DHO-180) and Other Ergot Derivatives." California medicine vol. 72,4 (1950): 234-8.
Bercel NA. TREATMENT OF MIGRAINE-Results with Dihydroergocornine Methanesulfonate (DHO-180) and Other Ergot Derivatives. Calif Med. 1950 Apr;72(4):234-8. PMID: 18731688; PMCID: PMC1520523.
Copy Download .nbib Format: NLM
Showing 25 to 36 of 48 entries